Stemedica Cell Technologies, an adult allogeneic stem cell manufacturing, research and development company, has received IRB approval from the University of California, San Diego (UCSD) to initiate a phase I/II, multi-center, open-label clinical study to assess the safety, tolerability and preliminary efficacy of a single intravenous dose of allogeneic mesenchymal bone marrow cells to subjects with Ischemic Stroke.

This study will enroll approximately 35 subjects with a clinical diagnosis of ischemic stroke.